In vitro potential modulation of baicalin and baicalein on P-glycoprotein activity and expression in Caco-2 cells and rat gut sacs

References

• Alam MA, Al-Jenoobi FI, Al-mohizea AM. 2012. Everted gut sac model as a tool in pharmaceutical research: limitations and applications. J Pharm Pharmacol. 64:326–336.
   PubMed Web of Science ®Google Scholar
• Bark H, Xu HD, Kim SH, Yun J, Choi CH. 2008. P-glycoprotein down-regulates expression of breast cancer resistance protein in a drug-free state. FEBS Lett. 582:2595–2600.
   PubMed Web of Science ®Google Scholar
• Binkhathlan Z, Lavasanifar A. 2013. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets. 13:326–346.
   PubMed Web of Science ®Google Scholar
• Carreno-Gomez B, Duncan R. 2000. Everted rat intestinal sacs: a new model for the quantitation of P-glycoprotein mediated-efflux of anticancer agents. Anticancer Res. 20:3157–3161.
   PubMed Web of Science ®Google Scholar
• Chieli E, Romiti N, Cervelli F, Tongiani R. 1995. Effects of flavonols on P-glycoprotein activity in cultured rat hepatocytes. Life Sci. 57:1741–1751.
   PubMed Web of Science ®Google Scholar
• Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, Starling JJ. 1996. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 56:4171–4179.
   PubMed Web of Science ®Google Scholar
• Fox E, Bates SE. 2007. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther. 7:447–459.
   PubMed Web of Science ®Google Scholar
• Fromm MF. 2000. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther. 38:69–74.
   PubMed Web of Science ®Google Scholar
• Fu LW, Liang YJ, Chen LM. 2006. Reversal of multidrug resistance by a novel third generation modulator, FG020326. Proc Am Assoc Cancer Res Annu Meet. 47:1271–1272.
   Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu XY, Dahlin A, Evers R, Fischer V, Hillgren KM, et al. 2010. Membrane transporters in drug development. Nat Rev Drug Discov. 9:215–236.
   PubMed Web of Science ®Google Scholar
• Hidalg IJ, Raub TJ, Borchardt RT. 1989. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology. 96:736–749.
   PubMed Web of Science ®Google Scholar
• Ise W, Heuser M, Sanders KH, Beck J, Gekeler V. 1996. P-glycoprotein-associated resistance to taxol and taxotere and its reversal by dexniguldipine-HCl, dexverapamil-HCl, or cyclosporin A. Int J Oncol. 8:951–956.
   PubMed Web of Science ®Google Scholar
• Kuppens IELM, Witteveen EO, Jewell RC, Radema SA, Paul EM, Mangum SG, Beijnen JH, Voest EE, Schellens JH. 2007. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res. 13:3276–3285.
   PubMed Web of Science ®Google Scholar
• Lassoued MA, Sfar S, Bouraoui A, Khemiss F. 2012. Absorption enhancement studies of clopidogrel hydrogen sulphate in rat everted gut sacs. J Pharm Pharmacol. 64:541–552.
   PubMed Web of Science ®Google Scholar
• Lomovskaya O, Bostian KA. 2006. Practical applications and feasibility of efflux pump inhibitors in the clinic – a vision for applied use. Biochem Pharmacol. 71:910–918.
   PubMed Web of Science ®Google Scholar
• Lopez D, Martinez-Luis S. 2014. Marine natural products with P-glycoprotein inhibitor properties. Mar Drugs. 12:525–546.
   PubMed Web of Science ®Google Scholar
• McDevitt CA, Callaghan R. 2007. How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther. 113:429–441.
   PubMed Web of Science ®Google Scholar
• Molden E, Christensen H, Sund RB. 2000. Extensive metabolism of diltiazem and P-glycoprotein-mediated efflux of desacetyl-diltiazem (M1) by rat jejunum in vitro. Drug Metab Dispos. 28:107–109.
   PubMed Web of Science ®Google Scholar
• Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 65:55–63.
   PubMed Web of Science ®Google Scholar
• Naito M, Watanabe T, Tsuge H, Koyama T, Oh-Hara T, Tsuruo T. 1996. Potentiation of the reversal activity of SDZ PSC833 on multi-drug resistance by an anti-P-glycoprotein monoclonal antibody MRK-16. Int J Cancer. 67:435–440.
   PubMed Web of Science ®Google Scholar
• Nito S. 1989. Enhancement of cytogenefic and cytotoxic effects on multidrug-resistant (mar) cells by a calcium-antagonist (verapamil). Mutat Res. 227:73–79.
   PubMed Web of Science ®Google Scholar
• Ozben T. 2006. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 580:2903–2909.
   PubMed Web of Science ®Google Scholar
• Perloff MD, Störmer E, von Moltke LL, Greenblatt DJ. 2003. Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm Res. 20:1177–1183.
   PubMed Web of Science ®Google Scholar
• Shapiro AB, Ling V. 1997. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol. 53:587–596.
   PubMed Web of Science ®Google Scholar
• Shen Q, Lin YL, Handa Y, Doi M, Sugie M, Wakayama K, Okada N, Fujita T, Yamamoto A. 2006. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int J Pharm. 313:49–56.
   PubMed Web of Science ®Google Scholar
• Sun WJ, Zhang YJ, Yao N, Jiang H, Wang Q. 2008. Influence on rat intestinal absorption of huanglian alkalis after match-pair of huanglian-wuzhuyu. Chin J Chin Mater Med. 33:2614–2616.
   Google Scholar
• Wei LY, Li J, Liu XY, Li ZH, Cao YL, Lin HY, Yang J, Zhang YJ. 2012. Induction of P-glycoprotein in rat jejunum by combined use of Coptis-scute herb. Chin J Exp Tradit Med Form. 18:141–146.
   Google Scholar
• Xing SH, Wang MY, Peng Y, Chen DF, Li XB. 2014. Simulated gastrointestinal tract metabolism and pharmacological activities of water extract of Scutellaria baicalensis roots. J Ethnopharmacol. 152:183–189.
   PubMed Web of Science ®Google Scholar
• Yan M, Li LF, Li HD, Fang PF, Xu P, Zheng M, Xu DH. 2012. Effect of 18α-glycyrrhizic acid and 18β-glycyrrhizic acid on P-gp function and expression in Caco-2 cells. Chin J Chin Mater Med. 37:99–103.
   Google Scholar
• Yanagisawa T, Newman A, Coley H, Renshaw J, Pinkerton CR, Pritchard-Jones K. 1999. Biricodar (VX-710; Incel): an effective chemosensitizer in neuroblastoma. Br J Cancer. 80:1190–1196.
   PubMed Web of Science ®Google Scholar
• Zakeri-Milani P, Valizadeh H, Islambulchilar Z, Damani S, Mehtari M. 2008. Investigation of the intestinal permeability of ciclosporin using the in situ technique in rats and the relevance of P-glycoprotein. Arzneimittelforschung. 58:188–192.
   PubMed Web of Science ®Google Scholar
• Zhang S, Morrism E. 2003. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther. 304:1258–1267.
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Yang J, Zou XC, Liu LM, Sun WJ. 2007. Influence of match-pair of huanglian-rougui on rat intestinal absorption of total huanglian alkali. Chin J Chin Mater Med. 32:1521–1524.
   Google Scholar
• Zhu H, Wang JS, Markowitz JS, Donovan JL, Gibson BB, Gefroh HA, Devane CL. 2006. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J Pharmacol Exp Ther. 317:850–857.
   PubMed Web of Science ®Google Scholar